1-Year Safety of 3-Month Dual Antiplatelet Therapy Followed by Aspirin or P2Y12 Receptor Inhibitor Monotherapy Using a Bioabsorbable Polymer Sirolimus-Eluting Stent
Open Access
- 25 December 2020
- journal article
- research article
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 85 (1), 19-26
- https://doi.org/10.1253/circj.cj-20-0644
Abstract
Background:This study evaluated the safety of 3-month dual antiplatelet therapy (DAPT) after implantation of a bioresorbable polymer sirolimus-eluting stent (BP-SES) and compared P2Y12inhibitor with aspirin monotherapy 3 months after DAPT. Methods and Results:Patients who underwent percutaneous coronary intervention using BP-SES were enrolled and followed for 1 year. Patients with a history of stent thrombosis were excluded. The primary endpoint was a composite of all-cause death, myocardial infarction, stroke (ischemic and hemorrhagic), definite or probable stent thrombosis, and severe bleeding at 12 months. The BP-SES arm of the CENTURY II trial was used as a conventional DAPT group for comparison. After DAPT, patients were maintained on either aspirin (n=846) or a P2Y12inhibitor (n=674 patients). In all, 1,695 patients were enrolled in the study across 65 centers. The primary endpoint occurred in 4.3% of patients at 1 year. After propensity score adjustment, the incidence of the primary endpoint was not inferior in those receiving DAPT for 3 months compared with conventional DAPT (5.5%; Pnon-inferiority12inhibitor monotherapy groups. Conclusions:After adjustment, 3-month DAPT was not inferior to longer DAPT after BP-SES implantation in terms of net adverse clinical events. There was no difference in bleeding and thrombotic events between P2Y12inhibitor and aspirin monotherapy after 3 months DAPT.Keywords
This publication has 27 references indexed in Scilit:
- A randomized, prospective, intercontinental evaluation of a bioresorbable polymer sirolimus-eluting coronary stent system: the CENTURY II (Clinical Evaluation of New Terumo Drug-Eluting Coronary Stent System in the Treatment of Patients with Coronary Artery Disease) trialEuropean Heart Journal, 2014
- Pathology of Second-Generation Everolimus-Eluting Stents Versus First-Generation Sirolimus- and Paclitaxel-Eluting Stents in HumansJournal of the American College of Cardiology, 2014
- A New Strategy for Discontinuation of Dual Antiplatelet TherapyJournal of Invasive Cardiology, 2012
- Short- Versus Long-Term Duration of Dual-Antiplatelet Therapy After Coronary StentingJournal of the American College of Cardiology, 2012
- Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysisThe Lancet, 2012
- Standardized Bleeding Definitions for Cardiovascular Clinical TrialsJournal of the American College of Cardiology, 2011
- Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trialsThe Lancet, 2009
- Clinical End Points in Coronary Stent TrialsJournal of the American College of Cardiology, 2007
- Aspirin and Platelets: The Antiplatelet Action of Aspirin and Its Role in Thrombosis Treatment and ProphylaxisSeminars in Thrombosis and Hemostasis, 1997
- A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)The Lancet, 1996